Publications by authors named "Michael Twahier Nurmohamed"
Article Synopsis
- Millions of patients use TNF inhibitors for inflammatory diseases, but the effectiveness varies due to differences in how drugs are cleared from the body, which may be influenced by TNF-TNFi complexes.
- Researchers focused on understanding how different types of TNF inhibitors, particularly their structural characteristics, affect the clearance and levels of TNF in patients with conditions like arthritis and ulcerative colitis.
- Findings indicate that TNF levels are significantly higher with certolizumab compared to other inhibitors, and the ability of macrophages to internalize these complexes is linked to the antibody structure, impacting TNF's clearance rate but not its production.
Long-Term Treatment With TNF-Alpha Inhibitors Improves Bone Mineral Density But Not Vertebral Fracture Progression in Ankylosing Spondylitis.
Kimberley Johanna Beek Tamara Rusman Maria Alida Cornelia van der Weijden Willem Frederik Lems Johannes Christiaan van Denderen Michael Twahier Nurmohamed
J Bone Miner Res
June 2019
The aim of this cohort study was to evaluate the long-term effects of TNF inhibitors (TNFis) on BMD and the incidence of vertebral fractures (VFxs) in patients with ankylosing spondylitis (AS). Consecutive patients with active AS with TNFi treatment duration up to 4 years with available DXA scans and spine X-rays were included. BMD (classified according to the WHO criteria for osteoporosis) of the hip and lumbar spine, the VFx (classified as a Genant score >1/>20% height loss), and radiological progression (modified stoke ankylosing spondylitis spinal score [mSASSS]) scores were obtained at baseline and at 4 years of TNFi treatment.
View Article and Find Full Text PDF